Skip to main content
Erschienen in: Journal of Neurology 11/2012

01.11.2012 | Original Communication

FabryScan: a screening tool for early detection of Fabry disease

verfasst von: Kathrin Arning, Dennis Naleschinski, Rainer Maag, Marieke Biegstraaten, Peter Kropp, Jürgen Lorenzen, Carla E. M. Hollak, Ivo N. van Schaik, Pontus Harten, Rainald A. Zeuner, Andreas Binder, Ralf Baron

Erschienen in: Journal of Neurology | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Abstract

Fabry disease, an X-linked lipid storage disorder, is associated early morbidity and mortality. Since enzyme replacement therapy is available, accurate detection of unrecognized cases is important. Characteristic early symptoms are recurrent episodes of burning and lancinating pain in the distal extremities associated with small fiber neuropathy. The aim was to develop and validate an easy diagnostic questionnaire in combination with three simple bedside tests, the “FabryScan”, for the detection of Fabry disease in patients with chronic extremity pain. Questions related to relevant clinical characteristics of Fabry disease (mainly related to pain) were compiled by Fabry specialists and pain experts. Furthermore, three bedside tests assessing sensory small and large fiber function were established. The provisional version was tested in a prospective multicenter trial of 138 patients with chronic extremity pain due to Fabry disease (n = 55), painful polyneuropathy (n = 40), and rheumatoid arthritis (n = 43). Identification of the most discriminant combinations of items for Fabry disease and their calculation of sensitivity and specificity were based on multivariate analyses. We retained only 10 questions and three bedside tests for the final version of the FabryScan. A cut-off score of 12/33 (corresponding to the number of positive points) resulted in a high proportion of correctly identified patients (76 %) with a sensitivity of 88 % and a specificity of 87 %. The FabryScan is a combination of a brief and simple questionnaire with three simple bedside tests with good discriminative value for the identification of Fabry patients in patients with chronic extremity pain.
Literatur
2.
Zurück zum Zitat Rolfs A et al (2005) Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366(9499):1794–1796PubMedCrossRef Rolfs A et al (2005) Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 366(9499):1794–1796PubMedCrossRef
4.
Zurück zum Zitat Scriver CR, Beaudet AL, Sly WS et al (eds) (2001) The metabolic and molecular bases of inherited disease, 8th edn. McGraw, New York Scriver CR, Beaudet AL, Sly WS et al (eds) (2001) The metabolic and molecular bases of inherited disease, 8th edn. McGraw, New York
5.
Zurück zum Zitat Spada M et al (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79(1):31–40PubMedCrossRef Spada M et al (2006) High incidence of later-onset fabry disease revealed by newborn screening. Am J Hum Genet 79(1):31–40PubMedCrossRef
6.
Zurück zum Zitat Aerts JMGJ et al (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 105:2812–2817PubMedCrossRef Aerts JMGJ et al (2008) Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA 105:2812–2817PubMedCrossRef
7.
Zurück zum Zitat Lee BHHS et al (2010) Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns. J Hum Genet 55:512–517PubMedCrossRef Lee BHHS et al (2010) Mutations of the GLA gene in Korean patients with Fabry disease and frequency of the E66Q allele as a functional variant in Korean newborns. J Hum Genet 55:512–517PubMedCrossRef
8.
9.
Zurück zum Zitat Mehta A et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34(3):236–242PubMedCrossRef Mehta A et al (2004) Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34(3):236–242PubMedCrossRef
10.
Zurück zum Zitat Lacomis D, Roeske-Anderson L, Mathie L (2005) Neuropathy and Fabry’s disease. Muscle Nerve 31(1):102–107PubMedCrossRef Lacomis D, Roeske-Anderson L, Mathie L (2005) Neuropathy and Fabry’s disease. Muscle Nerve 31(1):102–107PubMedCrossRef
11.
Zurück zum Zitat Mehta A et al (2010) Fabry disease: a review of current management strategies. QJM 103(9):641–659PubMedCrossRef Mehta A et al (2010) Fabry disease: a review of current management strategies. QJM 103(9):641–659PubMedCrossRef
12.
Zurück zum Zitat Eng CM et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A—replacement therapy in Fabry’s disease. N Engl J Med 345(1):9–16PubMedCrossRef Eng CM et al (2001) Safety and efficacy of recombinant human alpha-galactosidase A—replacement therapy in Fabry’s disease. N Engl J Med 345(1):9–16PubMedCrossRef
13.
Zurück zum Zitat Schiffmann R et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285(21):2743–2749PubMedCrossRef Schiffmann R et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285(21):2743–2749PubMedCrossRef
14.
Zurück zum Zitat Waldek S et al (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry registry. Genet Med 11(11):790–796PubMedCrossRef Waldek S et al (2009) Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry registry. Genet Med 11(11):790–796PubMedCrossRef
15.
Zurück zum Zitat Mehta A et al (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet 374(9706):1986–1996PubMedCrossRef Mehta A et al (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data. Lancet 374(9706):1986–1996PubMedCrossRef
16.
Zurück zum Zitat Moller AT, Jensen TS (2007) Neurological manifestations in Fabry’s disease. Nat Clin Pract Neurol 3(2):95–106PubMedCrossRef Moller AT, Jensen TS (2007) Neurological manifestations in Fabry’s disease. Nat Clin Pract Neurol 3(2):95–106PubMedCrossRef
17.
Zurück zum Zitat Ginsberg L (2006) Nervous system manifestations of Fabry disease: data from FOS—the Fabry outcome survey Ginsberg L (2006) Nervous system manifestations of Fabry disease: data from FOS—the Fabry outcome survey
18.
Zurück zum Zitat Hilz MJ (2002) Evaluation of peripheral and autonomic nerve function in Fabry disease. Acta Paediatr Suppl 91(439):38–42PubMedCrossRef Hilz MJ (2002) Evaluation of peripheral and autonomic nerve function in Fabry disease. Acta Paediatr Suppl 91(439):38–42PubMedCrossRef
19.
Zurück zum Zitat Rolke R et al (2006) Quantitative sensory testing in the German research network on neuropathic pain (DFNS): standardized protocol and reference values. Pain 123(3):231–243PubMedCrossRef Rolke R et al (2006) Quantitative sensory testing in the German research network on neuropathic pain (DFNS): standardized protocol and reference values. Pain 123(3):231–243PubMedCrossRef
20.
Zurück zum Zitat Maier C et al (2010) Quantitative sensory testing in the German research network on neuropathic pain (DFNS): somatosensory abnormalities in 1,236 patients with different neuropathic pain syndromes. Pain 150(3):439–450PubMedCrossRef Maier C et al (2010) Quantitative sensory testing in the German research network on neuropathic pain (DFNS): somatosensory abnormalities in 1,236 patients with different neuropathic pain syndromes. Pain 150(3):439–450PubMedCrossRef
21.
Zurück zum Zitat Maag R et al (2008) Detection of a characteristic painful neuropathy in Fabry disease: a pilot study. Pain Med 9(8):1217–1223PubMedCrossRef Maag R et al (2008) Detection of a characteristic painful neuropathy in Fabry disease: a pilot study. Pain Med 9(8):1217–1223PubMedCrossRef
22.
Zurück zum Zitat Dutsch M et al (2002) Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol 19(6):575–586PubMedCrossRef Dutsch M et al (2002) Small fiber dysfunction predominates in Fabry neuropathy. J Clin Neurophysiol 19(6):575–586PubMedCrossRef
23.
Zurück zum Zitat Biegstraaten M et al (2011) The relation between small nerve fibre function, age, disease severity and pain in Fabry disease. Eur J Pain 15(8):822–829PubMedCrossRef Biegstraaten M et al (2011) The relation between small nerve fibre function, age, disease severity and pain in Fabry disease. Eur J Pain 15(8):822–829PubMedCrossRef
24.
Zurück zum Zitat Aletaha D et al (2010) Rheumatoid arthritis classification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 69(9):1580–1588PubMedCrossRef Aletaha D et al (2010) Rheumatoid arthritis classification criteria: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 69(9):1580–1588PubMedCrossRef
25.
Zurück zum Zitat England JD et al (2005) Distal symmetric polyneuropathy: a definition for clinical research: report of the American academy of neurology, the American association of electrodiagnostic medicine, and the American academy of physical medicine and rehabilitation. Neurology 64(2):199–207PubMedCrossRef England JD et al (2005) Distal symmetric polyneuropathy: a definition for clinical research: report of the American academy of neurology, the American association of electrodiagnostic medicine, and the American academy of physical medicine and rehabilitation. Neurology 64(2):199–207PubMedCrossRef
26.
Zurück zum Zitat Whybra C et al (2004) The mainz severity score index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65(4):299–307PubMedCrossRef Whybra C et al (2004) The mainz severity score index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin Genet 65(4):299–307PubMedCrossRef
27.
Zurück zum Zitat Schwarzer G, Türp JC, Antes G (2002) EbM-Splitter: nutzen diagnostischer tests in der praxis: prädiktive Werte. Dtsch Zahnärztl Z 57:573–575 Schwarzer G, Türp JC, Antes G (2002) EbM-Splitter: nutzen diagnostischer tests in der praxis: prädiktive Werte. Dtsch Zahnärztl Z 57:573–575
28.
Zurück zum Zitat Schwarzer G, Türp JC, Antes G (2002) EbM-Splitter: die vierfeldertafel (in diagnosestudien): sensitivität und Spezifität. Dtsch Zahnärztl Z 57:333 Schwarzer G, Türp JC, Antes G (2002) EbM-Splitter: die vierfeldertafel (in diagnosestudien): sensitivität und Spezifität. Dtsch Zahnärztl Z 57:333
29.
Zurück zum Zitat Schwarzer G, Türp JC, Antes G (2002) EbM-spliter: sensitivität und spezifität: die auswirkung der wahl des trennpunktes. Dtsch Zahnärztl Z 57:446–447 Schwarzer G, Türp JC, Antes G (2002) EbM-spliter: sensitivität und spezifität: die auswirkung der wahl des trennpunktes. Dtsch Zahnärztl Z 57:446–447
30.
Zurück zum Zitat Florkowski CM (2008) Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests. Clin Biochem Rev 29(1):83–87 Florkowski CM (2008) Sensitivity, specificity, receiver-operating characteristic (ROC) curves and likelihood ratios: communicating the performance of diagnostic tests. Clin Biochem Rev 29(1):83–87
31.
Zurück zum Zitat Cortina JM (1993) What is coefficient alpha? An examination of theory and applications. J Appl Psychol 78:98–104CrossRef Cortina JM (1993) What is coefficient alpha? An examination of theory and applications. J Appl Psychol 78:98–104CrossRef
32.
Zurück zum Zitat Lance CE, Butts MM, Michels LC (2006) The sources of four commonly reported cut off criteria: what did they really say? Organ Res Methods 9(2):202–220CrossRef Lance CE, Butts MM, Michels LC (2006) The sources of four commonly reported cut off criteria: what did they really say? Organ Res Methods 9(2):202–220CrossRef
33.
34.
Zurück zum Zitat Hwu WL et al (2009) Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A(IVS4+919G>A). Hum Mutat 30(10):1397–1405PubMedCrossRef Hwu WL et al (2009) Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A(IVS4+919G>A). Hum Mutat 30(10):1397–1405PubMedCrossRef
35.
Zurück zum Zitat Watt T et al (2004) Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry registry. Genet Med 12(11):703–712CrossRef Watt T et al (2004) Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry registry. Genet Med 12(11):703–712CrossRef
36.
Zurück zum Zitat Bennett MI et al (2007) Using screening tools to identify neuropathic pain. Pain 127(3):199–203PubMedCrossRef Bennett MI et al (2007) Using screening tools to identify neuropathic pain. Pain 127(3):199–203PubMedCrossRef
37.
Zurück zum Zitat Deegan PB et al (2006) Natural history of Fabry disease in females in the Fabry outcome survey. J Med Genet 43(4):347–352PubMedCrossRef Deegan PB et al (2006) Natural history of Fabry disease in females in the Fabry outcome survey. J Med Genet 43(4):347–352PubMedCrossRef
38.
Zurück zum Zitat Laaksonen SM et al (2008) Neuropathic symptoms and findings in women with Fabry disease. Clin Neurophysiol 119(6):1365–1372PubMedCrossRef Laaksonen SM et al (2008) Neuropathic symptoms and findings in women with Fabry disease. Clin Neurophysiol 119(6):1365–1372PubMedCrossRef
39.
Zurück zum Zitat Torvin Moller A et al (2009) Functional and structural nerve fiber findings in heterozygote patients with Fabry disease. Pain 145(1–2):237–245PubMedCrossRef Torvin Moller A et al (2009) Functional and structural nerve fiber findings in heterozygote patients with Fabry disease. Pain 145(1–2):237–245PubMedCrossRef
Metadaten
Titel
FabryScan: a screening tool for early detection of Fabry disease
verfasst von
Kathrin Arning
Dennis Naleschinski
Rainer Maag
Marieke Biegstraaten
Peter Kropp
Jürgen Lorenzen
Carla E. M. Hollak
Ivo N. van Schaik
Pontus Harten
Rainald A. Zeuner
Andreas Binder
Ralf Baron
Publikationsdatum
01.11.2012
Verlag
Springer-Verlag
Erschienen in
Journal of Neurology / Ausgabe 11/2012
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-012-6619-y

Weitere Artikel der Ausgabe 11/2012

Journal of Neurology 11/2012 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.